Contineum Therapeutics Reports Positive Topline Phase 1b PET Data for PIPE-791
Sept 18 (Reuters) - Contineum Therapeutics Inc CTNM.O:
CONTINEUM THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM PHASE 1B POSITRON EMISSION TOMOGRAPHY (PET) TRIAL OF PIPE-791
CONTINEUM THERAPEUTICS INC - PIPE-791 ACHIEVES HIGH BRAIN RECEPTOR OCCUPANCY
CONTINEUM THERAPEUTICS INC - PIPE-791 SHOWS CONSISTENT SAFETY AND TOLERABILITY PROFILE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Tradingkey







